ANI Pharmaceuticals Inc
ANIPHealthcare|Drug Manufacturers - Specialty & Generic|USA
$82.07
-1.68 (-2.01%)
DCF (FCF)
$45.65
Tangible Book
$1.43
Graham Number
$13.56
Clinical Trials (15)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07346079 Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares | Gout Arthritis, Gout Flare | P4 | Recruiting | 150 | RCT, Double-blind | Purified Cortophin Gel, 40 U, Purified Cortophin Gel 80 U |
| NCT05322070 Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis | Uveitis, Posterior | P4 | Active | 125 | Open-label | Fluocinolone Acetonide Intravitreal Implant 0.18 mg |
| NCT06539481 Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye. | Non-infectious Uveitis Affecting the Posterior Segment of the Eye | P4 | Recruiting | 25 | Open-label | fluocinolone acetonide 190 micrograms |
| NCT04469595 A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME) | Diabetic Macular Edema | P4 | Active | 300 | RCT, Double-blind | Iluvien 0.19 MG Drug Implant, Aflibercept |
| NCT05486468 The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment | Uveitis, Uveitis, Posterior | P3 | Recruiting | 30 | RCT, Double-blind | Yutiq 0.18 MG Drug Implant |
| NCT07121634 Cervical Ripening With Misoprostol vs Isosorbide Mononitrate ; A Parallel -Arm Randomized Controlled Trial | Cervical Ripening | N/A | Active | 80 | RCT, Single-blind | Misoprostol 25 µg Vaginal, Isosorbide Mononitrate |
| NCT02472366 A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy | Chronic Diabetic Macular Edema | P4 | Completed | 16 | Open-label | ILUVIEN |
| NCT02424019 Phase 4 IOP Signals Associated With ILUVIEN® | Diabetic Macular Edema (DME) | P4 | Completed | 153 | Open-label | ILUVIEN 0.19 MG |
| NCT01304706 Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study | Diabetic Macular Edema | P3 | Completed | 120 | Open-label | Fluocinolone Acetonide |
| NCT00344968 Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema | Diabetic Macular Edema | P3 | Completed | 956 | RCT, Double-blind | fluocinolone acetonide, Fluocinolone Acetonide |
| NCT00490815 Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema | Diabetic Macular Edema | P3 | Completed | 37 | RCT, Open-label | Fluocinolone Acetonide, Fluocinolone Acetonide |
| NCT00770770 Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina | Macular Edema, Retinal Vein Occlusion | P2 | Terminated | 20 | RCT, Double-blind | Fluocinolone Acetonide, Fluocinolone Acetonide |
| NCT00695318 Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy | Age-Related Macular Degeneration | P2 | Terminated | 17 | RCT, Double-blind | Fluocinolone Acetonide, Fluocinolone Acetonide |
| NCT02080091 Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies | Diabetic Macular Edema (DME) | Terminated | 25 | — | — | |
| NCT01998412 Iluvien Registry Safety Study | Chronic Diabetic Macular Oedema Considered Insufficiently Responsive to Available Therapies | Unknown | 559 | — | — |